{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-006312","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.870208+00:00","generated_at":"2026-06-01T23:34:42.596333+00:00","sec_items":["3.01","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dermata gets 180-day Nasdaq extension; files 1:15 reverse stock split to regain compliance","bullets":["Received Nasdaq extension until November 11, 2024 to meet $1.00 minimum bid price.","Reverse stock split (1:15) effective May 16, 2024 to increase per-share price.","Nasdaq warned delisting if compliance not regained by the November deadline.","Company cautions no assurance of regaining compliance or meeting other listing rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-006312","json":"https://secwatch.observer/filing/0001654954-24-006312.json","markdown":"https://secwatch.observer/filing/0001654954-24-006312.md","text":"https://secwatch.observer/filing/0001654954-24-006312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424006312/0001654954-24-006312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424006312/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:34:42.596333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04cd1234825dfdb1b026d1736f205e59736d1e18","claim":"Dermata Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"May 14, 2024, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to November 11, 2024, to regain compliance with the Minimum Bid Price Requirement. As previously disclosed on May 14, 2024, in order to regain compliance with the Minimum Bid Price Requirement, the Company has filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware which will effect, at 12:01 a.m. Eastern Time, on May 16, 2024, a one-for-fifteen (1:15) reverse stock split of the Co","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424006312/0001654954-24-006312-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}